Any current/future new fundraising through debt or equity?

No new equity fundraising is planned for the current or next financial year. Pharma capacity expansion is being done primarily through brownfield expansion, with no new major CAPEX except land acquisition. Land worth Rs. 11 crores was acquired recently for pharma expansion, indicating future greenfield expansion. Brownfield expansions involve adding machinery and capacities gradually, expected to be operational by July-August next year. Annual CAPEX for maintenance and expansions is projected at around Rs. 100-105 crores for the current year, down from previous years. No mention of new debt fu

Any current/future capex/capital investment/strategic investment?

Land acquisition for pharma expansion: 2.5 acres adjacent to Sultanpur unit, costing around Rs. 11 crores (Page 12). Pharma capacity expansion: Brownfield increase to 2,500 tons planned progressively next financial year; no new capex counted for next year's projections (Page 12-13). New pharma facility construction likely to start Dec-Jan; expected operational shape by next financial year's second half (Page 16). CAPEX guidance: Around Rs. 100-105 crores expected for the current year, down from Rs. 130-140 crores in prior years (Page 11). Maintenance CAPEX will continue, aligning close

Future growth expectations in sales/revenue/volumes?

Overall volume growth target of around 12% is aimed, with potential to maintain this in the near term. Paint volumes grew by about 12% in H1 FY26; Q3 expected to be similar to Q2, while Q4 anticipates double-digit growth. Food and FMCG segment targeting 15%-20% growth, supported by new Panipat plant operations starting in Q4. Pharma segment expected to grow from Rs. 35-40 crores in current year to Rs. 55-60 crores next year, with long-term potential of Rs. 150-180 crores by FY30/31. Pharma volumes and revenue expected to increase with brownfield expansion and new facility coming online

Future growth expectations in earnings/operating earnings/profits/EPS?

Food and FMCG segment EBITDA per kg expected to be steady around Rs. 70-75 (down from Rs. 75-80 earlier), with volume growth offsetting slight dip in realizations. Overall volume growth target maintained at about 12% for the full year, driven by pharma and food & FMCG segments. EBITDA margin improvements anticipated to sustain at around 40-41% in H2 FY26, up from 37.6% last year. Pharma segment revenue expected to rise significantly: Rs. 35-40 crores in FY26, targeting Rs. 55-60 crores next year, with long-term potential of Rs. 150-180 crores by FY30/31. EBITDA per kg for pharma segment estima

Current/ Expected Orderbook/ Pending Orders?

More than 50 pharma companies have visited Mold-Tek Packaging's premises. Around 20-25 of these companies have started buying in small or medium quantities. None of these clients contribute more than 10-20% individually; sales are well spread out. For bottles and caps, the company has 7-8 decent-size clients supplying around Rs. 25-30 lakhs per month each. Remaining 30 client approvals are done, but commercial trials will take a few more quarters. Two strategic pharma customers have started giving small pilot orders worth around Rs. 70-80 lakhs over 2-3 months with expected ramp-up in Q4. The

IN US

Sale is live|00:00:00left today

Mold-Tek Packaging LtdQ3 FY25Industrial Products

Mold-Tek Packaging Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹702P/E: 32.3Market Cap: ₹2.3K CrSector: Industrial Products

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Overall volume growth target of around 12% is aimed, with potential to maintain this in the near term.
→Paint volumes grew by about 12% in H1 FY26; Q3 expected to be similar to Q2, while Q4 anticipates double-digit growth.
→Food and FMCG segment targeting 15%-20% growth, supported by new Panipat plant operations starting in Q4.
→Pharma segment expected to grow from Rs. 35-40 crores in current year to Rs. 55-60 crores next year, with long-term potential of Rs. 150-180 crores by FY30/31.
→Pharma volumes and revenue expected to increase with brownfield expansion and new facility coming online FY27.
→EBITDA per kg for food and FMCG expected steady at Rs. 70-75; pharma EBITDA per kg around Rs. 100-120.
→North plant to reduce supply cost/time, aiding growth and offsetting slight price realization pressure in food/FMCG.
→Overall sales value growth forecasted in the 12-15% range.

Margin guidance

Category 3

→Food and FMCG segment EBITDA per kg expected to be steady around Rs. 70-75 (down from Rs. 75-80 earlier), with volume growth offsetting slight dip in realizations.
→Overall volume growth target maintained at about 12% for the full year, driven by pharma and food & FMCG segments.
→EBITDA margin improvements anticipated to sustain at around 40-41% in H2 FY26, up from 37.6% last year.
→Pharma segment revenue expected to rise significantly: Rs. 35-40 crores in FY26, targeting Rs. 55-60 crores next year, with long-term potential of Rs. 150-180 crores by FY30/31.
→EBITDA per kg for pharma segment estimated around Rs. 100-120.
→EBITDA per kg company-wide expected to stabilize at Rs. 40-42 in H2, improving from around Rs. 37.6 last year.
→CAPEX planned around Rs. 100-105 crores for FY26, supporting capacity expansions, especially in pharma.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→No new equity fundraising is planned for the current or next financial year.
→Pharma capacity expansion is being done primarily through brownfield expansion, with no new major CAPEX except land acquisition.
→Land worth Rs. 11 crores was acquired recently for pharma expansion, indicating future greenfield expansion.
→Brownfield expansions involve adding machinery and capacities gradually, expected to be operational by July-August next year.
→Annual CAPEX for maintenance and expansions is projected at around Rs. 100-105 crores for the current year, down from previous years.
→No mention of new debt fundraising; expansions appear to be funded through internal accruals or existing resources.
→The company expects gradual capacity increases without sudden large capital inflows.

Order book

→More than 50 pharma companies have visited Mold-Tek Packaging's premises.
→Around 20-25 of these companies have started buying in small or medium quantities.
→None of these clients contribute more than 10-20% individually; sales are well spread out.
→For bottles and caps, the company has 7-8 decent-size clients supplying around Rs. 25-30 lakhs per month each.
→Remaining 30 client approvals are done, but commercial trials will take a few more quarters.
→Two strategic pharma customers have started giving small pilot orders worth around Rs. 70-80 lakhs over 2-3 months with expected ramp-up in Q4.
→The company has signed one major contract at Panipat for food and FMCG, expected to add Rs. 4-5 crores turnover next financial year.
→No significant export order cancellations due to tariffs; export levels remain negligible around Rs. 2-3 crores annually.

Capex plans

Yes

→Land acquisition for pharma expansion: 2.5 acres adjacent to Sultanpur unit, costing around Rs. 11 crores (Page 12).
→Pharma capacity expansion: Brownfield increase to 2,500 tons planned progressively next financial year; no new capex counted for next year's projections (Page 12-13).
→New pharma facility construction likely to start Dec-Jan; expected operational shape by next financial year's second half (Page 16).
→CAPEX guidance: Around Rs. 100-105 crores expected for the current year, down from Rs. 130-140 crores in prior years (Page 11).
→Maintenance CAPEX will continue, aligning close to depreciation (~Rs. 35-40 crores annually) (Page 12).
→Paint segment capacity: Total capacity for ABG (paints) ~10,000 tons across 3 plants, currently at ~60-65% utilization (Page 7).
→IML operations consolidated at Sultanpur expected to drive cost efficiencies starting Q3-Q4 (Page 7).

How does Mold-Tek Packaging Ltd rank vs peers in Industrial Products?

Pro feature

1Mold-Tek Packaging Ltd

Rev 3Mar 3

See full Industrial Products sector rankings

Want more stocks like Mold-Tek Packaging Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio